Showing 280 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

How Long-Acting Injectables Are Changing HIV Care

Editor's pick
American Journal of Managed Care
4 September 2026
Injectable & long-acting HIV treatment

AIDS 2026: Once-weekly tablet for HIV treatment Video

July 2026
Injectable & long-acting HIV treatment

Once-weekly islatravir / lenacapavir combination pill maintains HIV viral suppression

News
30 July 2026
Injectable & long-acting HIV treatment

Islatravir plus ulonivirine shows promise for weekly oral HIV treatment

News
30 July 2026
Injectable & long-acting HIV treatment

Long-acting injectable treatment superior to daily pills for adolescents in African trial

News
30 July 2026
Access to healthcare

Accelerating Access to Long-Acting HIV Medicines: A New Roadmap for Global Health

Editor's pick
Medicines Patent Pool
8 July 2026
New & experimental HIV treatments

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Editor's pick
Gilead Sciences press release
9 June 2026
People with limited treatment options

Can Long-Acting Regimens Solve Virologic Failure in Heavily Treatment-Experienced People With HIV?

Editor's pick
TheBodyPro
28 May 2026
New & experimental HIV treatments

Top 5 stories on the future of HIV treatment from CROI 2026

News
31 March 2026
New & experimental HIV treatments

New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment

News
6 March 2026
HIV treatment for children & young people

African paediatric studies at CROI: HIV remission in children, three bnAbs in babies, two years on injectables in teens

News
6 March 2026
Antibody-based treatment

Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year

News
2 March 2026
HIV treatment for children & young people

Injectable ART Suppressed HIV Long-Term in Teens

Editor's pick
MedPage Today
27 February 2026
Injectable & long-acting HIV treatment

Lenacapavir Resistance May Impair HIV Fitness

Editor's pick
POZ
12 January 2026
Injectable & long-acting HIV treatment

Gilead ends phase 1 trial after settling on twice-yearly treatment partner for lenacapavir

Editor's pick
FierceBiotech
3 November 2025
Treatment guidelines

BHIVA publish 2025 interim update of ART guidelines for adults

Editor's pick
i-Base
22 October 2025
Resistance

Resistance following failure of injectable cabotegravir/rilpivirine may limit future treatment options

News
22 October 2025
Injectable & long-acting HIV treatment

Are Cabotegravir Injections More Tolerable Than Lenacapavir?

Editor's pick
POZ
21 October 2025
Injectable & long-acting HIV treatment

Large, Diverse Study Backs Use of Long-Acting Injectable ART for Individuals With Viremia

Editor's pick
TheBodyPro
24 July 2025
Antibody-based treatment

Broadly neutralising antibodies plus immune modulator may delay HIV rebound

News
21 July 2025
Injectable & long-acting HIV treatment

Injectable HIV treatment works for people with poor HIV control in Africa

News
17 July 2025
Injectable & long-acting HIV treatment

ViiV Healthcare and Medicines Patent Pool extend voluntary licensing agreement to enable access to long-acting injectable HIV treatment

Editor's pick
Medicines Patent Pool
15 July 2025
Injectable & long-acting HIV treatment

Long-acting injectable HIV treatment highly effective in people with a detectable viral load and adherence challenges

Editor's pick
CATIE
17 June 2025
Injectable & long-acting HIV treatment

Potential for bictegravir and dolutegravir to overcome resistance to CAB/RPV-LA

Editor's pick
i-Base
14 April 2025